An Ag3 protein for the prevention and / or treatment of Mycoplasma pneumoniae infection and its application

By developing the Ag3 protein and its related components, preparing a vaccine, and conducting challenge experiments, the problem of unsatisfactory reduction of bacterial load in lung tissue by existing Mycoplasma pneumoniae vaccines was solved. The vaccine significantly reduced the bacterial load and inflammatory factor levels in the lungs, providing a valid basis for the development of Mycoplasma pneumoniae vaccines.

CN123106855APending Publication Date: 2026-11-17ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611628538.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing candidate antigens for Mycoplasma pneumoniae vaccines are not effective in reducing the key indicator of bacterial load in lung tissue, and lack effective protective effects, which limits the development of recombinant protein vaccines.

Method used

Develop an Ag3 protein and its related nucleic acid molecules, antigen proteins, fusion proteins, and vaccine adjuvants. Through vaccine preparation and challenge infection experiments, significantly reduce lung viral load and improve immune protection.

Benefits of technology

The Ag3 antigen protein can effectively induce antibody production, significantly reduce the bacterial load in the lungs of mice after challenge, decrease the level of inflammatory factors in lung tissue, and show little change in body weight, indicating its potential for development into a Mycoplasma pneumoniae vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106855A_ABST
    Figure CN123106855A_ABST
Patent Text Reader

Abstract

This invention relates to the field of vaccine development technology, and more particularly to an Ag3 protein for the prevention and / or treatment of Mycoplasma pneumoniae infection and its application. The invention provides an antigen protein, the amino acid sequence of which is shown in SEQ ID NO.3, or an amino acid sequence having at least 95% sequence identity with SEQ ID NO.3. The Ag3 antigen protein of this invention can effectively stimulate the production of antigen-specific antibodies. Ag3 levels are comparable to P1C antibody levels, and it can significantly reduce the number of bacteria in the lungs, reduce the concentrations of TNF-α and IL-1β in the lungs, and result in less weight loss after challenge infection compared to the adjuvant control group. The Ag3 antigen protein has the potential to be developed into a Mycoplasma pneumoniae vaccine, providing a valid basis for the development of Mycoplasma pneumoniae vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of vaccine development technology, and in particular to an Ag3 protein for the prevention and / or treatment of Mycoplasma pneumoniae infection and its application. Background Technology

[0002] Mycoplasma pneumoniae is one of the leading pathogens causing respiratory infections in children and adolescents. To date, there are no approved vaccines for Mycoplasma pneumoniae worldwide. Among various vaccine strategies, subunit recombinant protein vaccines are currently the main focus of research due to their well-defined composition, good safety profile, and ease of large-scale production. The development of recombinant protein vaccines is highly dependent on the selection of candidate antigens. Currently, the most frequently reported candidate antigens include adhesin P1, P30, and P116, helper adhesion proteins P40 / 90, community-acquired respiratory distress syndrome toxin (CARDS), and MPN133.

[0003] However, data on the protective efficacy of existing candidate antigens in animals are very limited, and the protective effects are not ideal. Lung tissue bacterial load is the most direct indicator of vaccine efficacy: Huang et al. systematically evaluated the immunogenicity of the above six proteins in BALB / c mice, suggesting that although they can induce high levels of specific antibodies, the in vivo protective effect was evaluated only by lung tissue pathological scores, without measuring lung tissue bacterial load, and pointed out that the above antigens "failed to provide complete protection against Mycoplasma pneumoniae infection" (Huang L, Zhang H, Xiao H, Li Z, Li Q. Immunogenicity Evaluation of Six Key Antigens of Mycoplasma pneumoniae In BALB / c Mice. Vaccines 2026, 14, 133); Wang et al. constructed a three-component recombinant subunit vaccine using P1, P40 / 90 complexes and attenuated CARDS toxin mutants. Even under aluminum adjuvant + CpG dual adjuvant conditions, the bacterial load in lung tissue after challenge was only reduced by about 71.7% compared to the control group, less than one order of magnitude, and the within-group standard deviation was close to the mean. The protective effect varied significantly among individual animals (Wang H, Wang T, Hou Z, Liu R, Liu Q, Zhou Z, Zhang B, Hou X, Li L, Wu J, et al. Three-Component Subunit Vaccine Induces Protective Immunity Against Mycoplasma pneumoniae(in Mice. Vaccines 2026, 14, 330). In summary, the limited number of candidate antigens available in the current technology that have a definitive protective effect on the key indicator of reduced bacterial load in lung tissue has become a major bottleneck restricting the development of recombinant protein vaccines for this bacterium.

[0004] Therefore, there is an urgent need to develop more candidate target proteins to provide more options for the development of Mycoplasma pneumoniae vaccines. Based on this, the present invention is proposed. Summary of the Invention

[0005] In response to the current shortage of Mycoplasma pneumoniae vaccines, this invention develops an Ag3 protein for the prevention and / or treatment of Mycoplasma pneumoniae infection and its applications.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: The present invention provides an antigen protein, the antigen protein having an amino acid sequence as shown in SEQ ID NO.3, or an amino acid sequence having at least 95% sequence identity with SEQ ID NO.3.

[0007] The present invention also provides a nucleic acid molecule comprising a nucleotide sequence encoding the antigen protein described above, wherein the nucleotide encoding the amino acid sequence shown in SEQ ID NO.3 is shown in SEQ ID NO.19.

[0008] The present invention also provides the use of the said antigen protein or said nucleic acid molecule in the preparation of vaccines for the prevention and / or treatment of Mycoplasma pneumoniae infection.

[0009] The present invention also provides the use of the antigen protein or the nucleic acid molecule in the preparation of antibodies against Mycoplasma pneumoniae infection, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

[0010] The present invention also provides a fusion protein comprising the antigen protein and an intramolecular adjuvant.

[0011] Preferably, the intramolecular adjuvant includes a CTB carrier or an LTB carrier.

[0012] The present invention also provides the use of the fusion protein in the preparation of vaccines for the prevention and / or treatment of Mycoplasma pneumoniae infection.

[0013] The present invention also provides the use of the fusion protein in the preparation of antibodies against Mycoplasma pneumoniae infection, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

[0014] The present invention also provides a vaccine comprising the said antigen protein or the said fusion protein and a vaccine adjuvant.

[0015] Preferably, the vaccine adjuvant comprises aluminum hydroxide and / or CpG2006.

[0016] The present invention also provides a composition comprising the antigen protein, the fusion protein, or the vaccine.

[0017] The present invention has the following advantages: The Ag3 antigen protein of this invention can effectively induce the body to produce antigen-specific antibodies, and the antibody level induced by Ag3 is comparable to that of P1C. A vaccine was prepared by mixing Ag3 with a vaccine adjuvant, and challenge infection experiments were conducted. The results showed that compared with the adjuvant control group, mice in the Ag3 vaccine immunization group experienced less weight loss after challenge, and the concentrations of TNF-α and IL-1β in lung tissue were significantly reduced. Quantitative detection of lung bacterial load confirmed that the bacterial load in the lungs of mice in the Ag3 vaccine immunization group was significantly lower than that in the adjuvant control group, corresponding to a decrease in pathogen load of approximately 3 times. In conclusion, the Ag3 antigen has the potential to be developed into a Mycoplasma pneumoniae vaccine, providing a valid basis for the development of Mycoplasma pneumoniae vaccines. Attached Figure Description

[0018] Figure 1 The results show the expression and purification of 16 candidate antigen proteins; Figure 2 The effects of 16 candidate antigen proteins on pathogen nucleic acids in lung tissue; Figure 3 Results of purity analysis of Ag3 effective antigen protein and P1C protein; Figure 4 To evaluate the level of antibody production stimulated by Ag3 effective antigen protein and P1C protein; Figure 5 The results show the changes in body weight of mice in each group after infection; Figure 6 The results show the levels of inflammatory factors in the lungs of mice in each group after infection; Figure 7 The results show the concentration of pathogens in the lungs of mice in each group after infection. Detailed Implementation

[0019] In this invention, the application of a reagent for detecting the expression level of the antigen protein shown in SEQ ID NO.3 in the preparation of products for evaluating the immunoprotective effect of the protein is also provided. The reagents include primer pairs and probes; The primer pairs are shown in SEQ ID NO.33~SEQ ID NO.34; The probe is shown in SEQ ID NO.35.

[0020] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0021] The sequences involved in the embodiments of the present invention are as follows: SEQ ID NO:1: ANINLISAVGSSSVQPLLSKLSSHYVLNHNDKDNLVEISVQAGGSSAGVKAITKGLADIGNVSKNTKSYAENKQLWMDKKLKTITLGKDAIAVIYKAPSEFKGKLVLTKDNLNDLYDLFAGSKSVDINKFVENGQTTKNSNHNLIGFPRTGGAFASGTAEAFLKFSGLTQTKTL DKDSKEILEGQRNYGPNARPTSETNIEAFNTFVTTLRQPNLYGMVYLSLGFVNNNMNLIKSEGFEVLKVKYDNNAVTPSSQAVSSNTYKWVRPLNSVVSLLPKQKTLPSIQRFFNWLLFSNNSEIKKIYDDFGVLELTADEKKKMFKTGNAEMSNIANFWVDDYSLNNQTFGAL.

[0022] SEQ ID NO:2: ARRESNHLIFNISLDHDADASISKFFELYSNNLSKKLDKKVTVSFNIIDDSFTKISNIQTAKADFAFVNSQSIKDNGIEGFNLILQTQTDAFKEDTNLDYYSDGQLKSKAEKMTTLFSKTPYKDWEDTAQQWTGSRYNFLYETNKLINFYRGMILITGSEEEIKKIKEAWDQKKWSD FMNYGIGHGSSGSAGKFQLPDLLLRKHFGSSYPGLQNAINQNPDKFANVRGREIGRDNKIKIVFDDANSFAWTHNDKNATNHFYTPTENNGKGDSEKSNNKNNKVEILTYTDPMLYDIGIVSDTLSDRYQKAIAEVFVELAKTKQDIYGPSYGYNGYNLITDPNKEILDVIHKTYG.

[0023] SEQ ID NO:3: SSTTSQVISSLSAQKYFEANKGELNKNNVINILKDGYNSDPNKTVNALLAGWKYTLMDQKLLENNLDPSRFKNTFGPNKNDVTPNISEKGLFLNETFTGLGSQIAEVFNVQKQIVSGFSYSWTSPKSFKVNIHIKMEGMINEKSKETIKSFLSNKDSNGSNSVEESEYTGDKAKFTADFIFSYTPPTGGTRSLTDKSFDVITNMINFPADVKIDVNTSHNKLNELLEKNDQVKRMKSRTFNGRNIDLLPFFYYALL.

[0024] SEQ ID NO:4: SNYDFQANLTSLNQLRTSANKDINLTQDKNTLIDALKTAFENNSEGTTKVLLDAWKFSLYDAKILEKQDPVKFVKAFGSGKSKEDIEPSAGVRGLRFVERFGDNTASLIKNAILLDQQKVEVFNIRFKSSRDFTIQIKLNAKGNYKKSEVEKYKSQIGLQDNELGDKEEGTLEADLIFTYTPPASNLFSKSNFDKLTKSINFNTNLKLEMVGKDEVMRKILNSAFTNNLASVNYPNQAVNLLPYVLYSIL.

[0025] SEQ ID NO:5: SSATTEVISSFSSAQKYFSANKELNKRNLVTILKDSYNDPKSTVNSLLAGWKYSLLDQKLLENPMDPSRFSKAFGSNTKDDVTPNISEKGLYLAETYPGVSSQIAQVLGVQSQKVTGFSYSWTSKTKFEV KILIKMKGKVGSDGTSQTLIKSFLGTDSKGSGSNNQNGGVTEKDFEGDQANFDGNFIFTYTQPSDGRRLASSNDFDPITGTINFPADLQIEVSTSHEKLNTLMTTNTQVGMIKNRSFKGKSFNLLPFFYYALL。

[0026] SEQ ID NO:6: SNSGFEANLTSLNQLRTSASKNTNLTQNKADLVTALKSAFENNPEGTTRVLLDAWKFTLLDAQILEKQDFSKFSKSFGSGRSIEDVEPSAGVRGLRLVERYTQDTANIINNVIKLDKQKVEAFSIQYKDPKNFRVQVKINAKGNYKKDTVKTYLSQVGLSDGDLNDTGTLEAEIIYTYMPPAASFFSASKFDKLTRAINFNTNLRIQIIGKDSVMTKLLQQSSFVKQLADQKFQDQSINLLPYVLYSIL。

[0027] SEQ ID NO:7: SSNQFVFANFESYVSPLLLERAEAKQPMTFLTYPTNEKLINGFANNTYTVAVASSYAVSELQQQGHLLPIDWAKFNLKKTQNGSNQATIQNKEDAKELFTKEIGDISGELLNWGVPYFLQDLVFVYRGEKIQELEGQDVTWSTIIKAIVNHKDRFNNNRLALIDDARTIFSLANVVHHEVKNTTVDVNPTGSTLNYFGNVYESFANLGLKRDNLNTLFVNSDSNIIINELANGRRQGGIVYNGDAVYAALGGDLRDEINENNLPNGDNFHIVQPKHSPVALDFLIINQQQTHFRDAAHQLIYQLALEGADQTAEELLKTDEEKGTSDEDYYTYGAMQNFSYVNYVSPLKNISDETTGIVFKENKQADTKRVVKQQSQSEQQSESAEKEETEQDDFYTATLKSLLKADSLDDKAKKLVDTIKKTYKIKKADNINWANLIEKPITPLQRSNLTLSWLDFKQRFW。

[0028] SEQ ID NO:8: AKLDKNQLIESLKEMTIMEIDEIIKAVEEAFGVSATPVVAAGAVGGTQEAASEVTVKVTGYADNAKLAVLKLYREIAGVGLMEAKTAVEKLPCVVKQDIKPEEAEELKKRFVEVGATVEIK。

[0029] SEQ ID NO:9: QPVPTALQRTGASAIHEGSFQTITLGQSLMEQIEQLQQFTPAQRFTQFKKKFPNQKLLSQSELSPVDVYNFLSGWQGALVSFLDRVIKLQGKVKEANEIFNPNVGDQIVLPKKENPNVLEVLGEYNGFGFFPTLGKNGLNLPQQIFENFTDFK VESYQINDFKVSLVGERDIIKNDKVRFSYAVQIPLNLELLVNNQKVTFNITVDLRTNNFSTQETFNDLFNNGTAPTNWQFFSRIKVNKLHYDQTDATHLANTLLQDQFNALNLDLQKSIYDLNLDGGLEERFEEYAKPLREKRTQQKKEWEEE。

[0030] SEQ ID NO:10: YTGIQADLRNLIKETTKKDIDVYKAIKTTEGKKNIITSLKKSYEVNPKDTTKLLLDAWKQSFEKGELGIPDLDFEDVIYPKTSEPFKFERKVDHFQMTYQSFKGLSIEAKLSYNFNWFGDYSSGGFTAKKGDKHYFDLFLKIKSNSDPKKQFTTEKFLTKEEKNKVNGKEITRNLEWIEFSASLSWLIKGKDDVSQKSVKQFLSSYANNTSGYSRDINLFIYLEYLIK.

[0031] SEQ ID NO:11: SSAATQVISSLSSAQKYFESSQGELNKKNVIKILKEGYESDANKAVHALLAGWKYTLMDQQLLSKEVDSRFIKAFGSGRDKGDVTPSVSEKGLYLNETYTGFSIQIAKVLGVLGVQSQTVKQFNYKWSSNSDFKVQIQISMKGKVGSDSESQQLIKSFLSSDNNGSNQNGVKETDFNGDSANFDGFFTFTYTPPTQSRKFGATSFDPLTTKINFPADLQIDVSTTHQKLNTLMEANEQVKQIKSRKFTGKTDFLLPPFFYYALL.

[0032] SEQ ID NO:12: AREKFDRSKPHVNVGTIGHIDHGKTTLTAAICTVLAKEGKSAATRYDQIDKAPEEKARGITINSAHVEYSSDRHYAHVDCPGHADYIKNMITGAAQMDGAILVVSATDSVMPQTREHILLARQVGVPRMVVFLNKCDIATDEEVQELVAEEVRDLLTSYGFDGKNTPIIYGSALKALEGDPKWEAKIHDLMNAVDEWIPTPEREVDKPFLLAIEDTMTITGRGTVVTGRVERGELKVGQEIEIVGLRPIRKAVVTGIEMFKKELDSAMAGDNAGVLLRGVDRKEVERGQVLAKPGSIKPHKKFKAEIYALKKEEGGRHTGFLNGYRPQFYFRTTDVTGSISLPENTEMVLPGDNTSITVELIAPIACEKGSKFSIREGGRTVGAGSVTEVLE.

[0033] SEQ ID NO:13: ANEFKFTDVGEGLHEGKVTEILKKVGDTIKVDEALFVVETDKVTTTELPSYAGVITAITTNVGDVVHIGQVMAVIDDGAGAAAPAAPQPVSAPAPAPTFTPTPAPVTTEPVVEEAGASVVGEIKVSNSVFPIFGVQPSAPQPTPAPVVQPTSAPTPTPAPAASAAAPSGEETIAITTMRKAIAEAMVKSHENIPATILTFYVNATKLKQYRESVNGLALSKYNMKISFFAFFVKAIVNALKKFPVFNGRYDKERNLIVLNKDVNVGIAVDTPDGLIVPNIKQAQTKSVVDIAKDIVDLANRARSKQIKLPDLSKGTISVTNFGSLGAAFGTPIIKHPEMCIVATGNMEERVVRAEGGVAVHTILPLTIAADHRWVDGADVGRFGKEIAKQIEELIDLEVA.

[0034] SEQ ID NO:14: ATPNTYEVQRAALIQLVEEDERQNYIQKGSIGANAVMTAAKAETKTAEKTATSTKAASIELKKTDTDIKTTTTENKSASGYKLDTLFGDYILWVVDHLSGLLFSPKTNNSTTTQKIQLITEDKVILDGGNLTVEKNHEHGHTHKNGETHEHDHDHHEGEEEVIVGRALSFANGLFLVVDLKEEKHEEKKEAKSEMSMNSKDMVMMTKTEMMSKEMKSEQKMEKKEEHEHHHKKLSLTTAYKFGQSFNILEFTGAMHKTAHNNETEFKNLGKKYGGMTEYTIVDFDFNPPKPTK.

[0035] SEQ ID NO:15: TGIQADLRNLIKEATGKDIDVYKAIKTTEGKKNMITSLKKSYKVNPKDTTKLLLDAWKQSAEKSELGIPDFDFDDVIYPASKDPFTMERKIEYFQMTYQSFKDLSIEAKLSYTFNWFGDYSSGDFTAKKGDKHYFDLFLKIKSNSDPGKQFTTEKFLTKEEKIKVNGKEITRNLEWIEFSASLSFSLKGKDDVSEKSVNKFLSTFANNTEGYSSDINLFIYLEYLIK.

[0036] SEQ ID NO:16: SSTATNVISSLSSAQKYFDAHKSELIKNVINLLKEGYSTDSKATVNSLFAGWKYTLMDQKILERNLDASRFTKAFGTNKGKDDVIPSISEKGLFLDETYSGVSQQIVKVLGVQSQKVTGFSYSWSSTTNFKVVISFMMQGIVGSGEESNSLIKSFLSSGNNGNVTENDFNNGNANFDGTFIFTFTPPTDGRRFAFSNFDPITGTINFPANLQIDASTTHEKLNILMQNNEHVKKIKSRSFTGKSDFLLPFYALL。

[0037] SEQ ID NO:17:

[0038] SEQ ID NO:18:

[0039] SEQ ID NO:19: AGCAGCACGACCAGCCAAGTGATCAGCAGCTTGAGCAGCGCACAGAAATACTTCGAGGCGAACAAAGGAGAGCTGAACAAGAATAACGTTATCAACATACTTAAAGACGGCTATAACTCTGATCCAAACAAGACTGTAAATGCACTGCTGGCCGGCTGGAAATATACCCTGATGGATCAAAAGTTGCTCGAGAACAACCTGGATCCTTCCCGCTTTAAGAATACGTTTGGTCCCAACAAAAACAAAGATGATGTGACCCCGAACATTTCGGAAAAAGGCCTGTTCTTAAACGAAACTTTTACTGGACTTGGCTCTCAGATTGCAGAGGTGTTTAATGTTCAGAAACAGATCGTGTCTGGCTTTAGCTATAGCTGGACGTCTCCAAAAAGCTTTAAGGTGAACATCCATATCAAAATGGAAGGGATGATTAACGAAAAATCCAAAGAAACCATTAAAAGCTTCCTCTCGAATAAGGATTCTAACGGCTCCAATTCTGTTGAGGAGTCGGAATATACCGGAGATAAAGCTAAATTCACAGCAGATTTTATCTTTAGTTATACTCCTCCAACTGGGGGAACCCGCTCACTTACCGATAAGAGCTTCGATGTGATCACCAACATGATCAACTTTCCAGCGGATGTTAAGATTGATGTTAATACCTCCCACAATAAACTGAACGAATTATTGGAGAAAAATGATCAGGTTAAACGTATGAAATCGCGTACCTTCAATGGGCGCAATATCGATCTCCTGCCGTTCTTCTACTATGCGCTTCTT。

[0040] SEQ ID NO:20: 。

[0041] SEQ ID NO:21: AGCAGCGCTACGACAGAAGTTATCAGCAGCTTTAGTAGTGCACAGAAATACTTCTCCGCGAACAAAAAGGAGCTGAACAAGCGTAACTTGGTGACCATTCTCAAAGACAGTTATAACTCTGATCCAAAGAGCACTGTAAATAGTCTGCTGGCCGGCTGGAAATATTCGCTGCTTGATCAAAAGTTGCTCGAGAACCCGATGGATCCTTCCCGCTTTAGCAAAGCGTTTGGTTCCAACACCAAAGACGATGTAACGCCCAACATCTCAGAAAAAGGTCTGTACCTGGCTGAAACCTATCCAGGTGTGTCCTCGCAAATCGCCCAGGTGCTGGGCGTTCAAAGCCAAAAGGTAACGGGTTTTTCTTACTCTTGGACGAGCAAAACCAAATTCGAAGTGAAGATCCTGATCAAAATGAAAGGTAAGGTAGGCTCGGATGGTACCTCTCAAACCCTCATTAAGAGCTTTCTCGGTACGGATTCTAAGGGCTCCGGCTCTAATAACCAGAACGGTGGTGTCACGGAAAAAGATTTCGAGGGCGATCAGGCCAACTTTGACGGTAATTTCATCTTTACGTACACCCAGCCATCCGATGGACGTCGCTTAGCCAGCTCGAATTTCGACCCGATCACAGGTACCATCAACTTCCCTGCTGATTTGCAGATTGAAGTAAGCACGAGCCATGAAAAACTCAACACCCTGATGACCACTAATACCCAGGTAGGTATGATCAAAAACCGCTCGTTTAAAGGCAAGTCGTTTAATCTCCTGCCGTTCTTTTACTATGCCCTCTTG。

[0042] SEQ ID NO:22: AGCAACTCTGGGTTCGAAGCCAACCTGACGTCTCTGAACCAGCTGCGTACCAGCGCGAGCAAAAATACGAACTTAACCCAGAATAAAGCTGACTTAGTTACTGCTCTGAAATCAGCGTTTGAAAATAACCCGGAAGGCACCACACGCGTGTTGCTGGACGCTTGGAAATTCACCCTGTTGGACGCCCAGATCCTGGAGAAACAAGATTTTAGCAAATTCTCCAAGTCATTTGGTAGTGGCCGTAGCATCGAAGACGTCGAGCCGTCAGCAGGTGTTCGCGGACTGCGTCTGGTCGAACGTTATACGCAAGATACTGCAAATATCATCAACAATGTTATTAAGTTGGACAAACAGAAAGTCGAAGCGTTTAGCATCCAGTATAAAGATCCGAAAAACTTTCGTGTTCAAGTGAAAATCAATGCGAAAGGCAACTATAAGAAGGATACTGTTAAAACTTACCTGTCGCAGGTCGGGCTTTCTGACGGCGATCTTAATGATACGGGGACCTTAGAAGCCGAGATCATTTATACGTACATGCCACCAGCGGCTTCCTTCTTTTCAGCAAGCAAATTCGACAAACTCACCCGTGCAATCAACTTCAACACCAACCTGCGTATACAGATCATCGGCAAAGATTCGGTTATGACCAAATTGTTGCAGCAAAGCTCATTTGTGAAGCAGTTAGCCGATCAGAAATTCCAGGATCAATCCATTAATCTCTTACCCTACGTTCTGTACTCGATCTTG。

[0043] SEQ ID NO:23:

[0044] SEQ ID NO:24: GCGAAACTGGACAAGAACCAGCTGATCGAAAGCCTGAAAGAAATGACTATCATGGAAATCGACGAAATCATCAAAGCTGTTGAAGAAGCTTTCGGCGTTAGCGCGACTCCGGTTGTTGCAGCAGGCGCTGTTGGTGGCACTCAAGAAGCAGCGTCTGAAGTGACCGTTAAAGTTACTGGCTACGCTGACAACGCTAAACTGGCGGTACTGAAACTGTACCGCGAAATCGCTGGTGTTGGCCTGATGGAAGCTAAGACCGCAGTTGAGAAACTGCCGTGCGTTGTTAAACAAGACATCAAACCGGAAGAAGCGGAAGAACTGAAGAAACGTTTCGTTGAAGTTGGTGCGACTGTTGAAATCAAG。

[0045] SEQ ID NO:25: CAGCCGGTGCCAACCGCGCTGCAGCGTACGGGTGCAAGCGCGATTCATGAAGGCAGCTTTCAGACCATTACCCTGGGCCAGAGCCTGATGGAACAGATTGAACAGCTGCAGCAGTTTACTCCGGCCCAACGCTTTACCCAGTTCAAAAAGAAGTTTCCGAACCAGAAACTGCTGAGCCAGAGCGAACTGAGCCCGGTGGATGTGTATAACTTTCTGAGCGGCTGGCAGGGTGCACTGGTGAGCTTTCTGGATCGCGTGATTAAACTGCAGGGCAAAGTGAAAGAAGCGAACGAAATTTTCAACCCGAACGTGGGCGATCAGATTGTGCTGCCGAAAAAAGAAAACCCGAACGTGCTGGAAGTGCTGGGCGAATATAACGGCTTTGGCTTTTTTCCGACCCTGGGCAAAAACGGCCTGAACCTGCCGCAGCAGATTTTTGAAAACTTTACCGATTTCAAAGTGGAAAGCTATCAGATTAACGATTTCAAAGTGAGCCTGGTGGGCGAACGCGATATTATCAAAAACGATAAAGTGCGCTTTAGCTATGCGGTGCAGATTCCGCTGAACCTGGAACTGCTGGTGAACAACCAGAAAGTGACCTTTAACATTACCGTGGATCTGCGCACCAACAACTTTAGCACCCAGGAAACCTTTAACGATCTGTTTAACAACGGCACCGCACCGACCAACTGGCAGTTTTTTAGCCGCATTAAAGTGAACAAACTGCATTATGATCAGACCGATGCGACCCATCTGGCGAACACCCTGCTGCAGGATCAGTTTAACGCGCTGAACCTGGATCTGCAGAAAAGCATTTATGATCTGAACCTGGATGGCCTGGAAGAACGCTTTGAAGAAGAATATGCGAAACCGCTGCGCGAAAAACGCACCCAGCAGAAAAAAGAATGGGAAGAAGAA。

[0046] SEQ ID NO:26: 。

[0047] SEQ ID NO:27: AGCAGCGCTGCGACACAAGTTATCAGCTCGCTCAGCAGTGCGCAGAAATACTTCGAGAGCAGTCAAGGAGAGCTGAACAAGAAAAACGTTATCAAAATTCTGAAAGAGGGCTATGAGTCTGATGCCAACAAGGCCGTACACGCCCTGCTGGCTGGCTGGAAATATACCCTGATGGATCAACAGTTGCTCAGTAAGGAGGTAGATTCTCGTTTCATTAAGGCCTTCGGTTCCGGTCGCGATAAAGGAGATGTAACGCCCAGCGTGTCAGAAAAAGGTCTGTACCTGAATGAAACCTATACCGGTTTCTCCATCCAAATCGCCAAAGTGCTGGGTGTCCAGAGCCAAACGGTAAAGCAGTTTAACTATAAATGGAGCAGCAATTCAGATTTCAAAGTGCAAATTCAAATTAGCATGAAAGGTAAGGTAGGCTCGGATTCTGAATCTCAACAACTCATTAAGAGCTTTCTCTCAAGCGATAATAACGGCTCCAATCAAAATGGTGGTGTGAAAGAAACCGACTTTAATGGTGACAGTGCAAATTTTGATGGATTTTTCACTTTTACATACACTCCGCCGACCCAGTCACGTAAATTTGGAGCGACATCATTCGATCCACTGACGACCAAAATCAATTTTCCAGCCGACTTGCAAATTGATGTCTCCACGACCCATCAGAAGCTCAATACCCTCATGGAAGCAAACGAACAAGTCAAACAGATCAAATCCCGCAAATTCACAGGCAAAACCTTTGACCTGCTGCCCTTTTTCTACTATGCCCTGTTA。

[0048] SEQ ID NO:28:

[0049] SEQ ID NO:29:

[0050] SEQ ID NO:30: 。

[0051] SEQ ID NO:31: 。

[0052] SEQ ID NO:32: AGCAGCACCGCGACCAACGTGATTAGCAGCCTGAGCAGCGCGCAGAAGTATTTTGATGCGCATAAAAGCGAACTGATTAAGAAAAACGTGATTAACCTGCTGAAAGAAGGCTATAGCACCGATAGCAAAGCGACCGTGAACAGCCTGTTTGCGGGCTGGAAATATACCCTGATGGATCAGAAAATTCTGGAACGCAACCTGGATGCGAGCCGCTTTACCAAAGCGTTTGGCACCAACAAAGGCAAAGATGATGTGATTCCGAGCATTAGCGAAAAAGGCCTGTTTCTGGATGAAACCTATAGCGGCGTGAGCCAGCAGATTGTGAAAGTGCTGGGCGTGCAGAGCCAGAAAGTGACCGGCTTTAGCTATAGCTGGAGCAGCACCACCAACTTTAAAGTGGTGATTAGCTTTATGATGCAGGGCATTGTGGGCAGCGGCGAAGAAAGCAACAGCCTGATTAAAAGCTTTCTGAGCAGCGGCAACAACGGCAACGTGACCGAAAACGATTTTAACAACGGCAACGCGAACTTTGATGGCACCTTTATCTTCACGTTTACCCCGCCAACCGATGGCCGTCGTTTTGCGTTTAGCAACTTTGATCCGATTACCGGCACCATTAACTTTCCGGCGAACCTGCAGATTGATGCGAGCACCACCCATGAAAAACTGAACATTCTGATGCAGAACAACGAACATGTGAAAAAGATTAAGAGCCGCAGCTTTACCGGCAAAAGCTTTGATCTGCTGCCGTTTTACTTCTATGCGCTGCTG。

[0053] SEQ ID NO:33: GCAGTTGCTGGCGCTAAGTT。

[0054] SEQ ID NO:34: AGCGAGGTACGGTAGCGGTAT。

[0055] SEQ ID NO:35: CTCGTTTTAGCGGGTACC。

[0056] Example 1

[0057] Screening and expression of candidate antigen proteins

[0058] The protein sequences of the representative Mycoplasma pneumoniae strain NCTC10119 (accession number NZ_LR214945) were downloaded. AlphaFold2 (https: / / github.com / google-deepmind / alphafold) was used to predict the structure of all 689 proteins. The AgtigenSieve algorithm (https: / / ai4biosciences.com / AntigenSieve / ) was used to predict and rank the antigenic immunoprotective efficacy of the proteins. Proteins with a prediction score above 0.7 underwent further testing. Two conditions were set: first, to ensure vaccine effectiveness, the protein must be conserved and present in more than 90% of the strain's genome; second, to facilitate expression in E. coli, the protein length was limited to less than 570 amino acids. Proteins with a length of 570 amino acids cover more than 75% of the positive proteins in the PLGDL dataset. The signal peptide sequences of the proteins meeting the conditions were predicted, and the N-terminal signal peptide was removed. In particular, for candidate antigens annotated as lipoproteins, the N-terminal signal peptide and lipidation sites need to be removed to avoid potential VED effects. The protein sequences of the candidate antigens were reverse-translated into nucleotide sequences, and after codon optimization for *E. coli*, they were inserted between the Nde I and Xho I restriction sites of the pET28a expression vector. The synthesis was entrusted to Beijing Qingke Biotechnology. The expression plasmid was transformed into the BL21(DE3) expression strain, and after IPTG induction, 16 recombinant lipoprotein proteins that could be expressed in the supernatant were obtained, as shown in Table 1.

[0059] Table 1 Information on 16 antigen proteins

[0060] The specific steps for IPTG-induced expression are as follows: (1) The expression strains of the above 16 candidate antigen proteins were inoculated into 5 mL LB Kana (50 μg / mL) medium and cultured overnight at 37℃ and 180 rpm. (2) Transfer the overnight cultured strain to 500 mL LB Kana (50 μg / mL) medium and incubate at 37°C and 180 rpm until OD. 600 =0.5; (3) Add IPTG to a final concentration of 1 mM and induce expression at 25°C and 180 rpm for 8 h; (4) Centrifuge the expressed bacterial culture at 8000 rpm for 10 min to collect the bacterial cells and discard the supernatant; (5) The bacterial cells were resuspended in 150 mL buffer A (20 mM PB, 0.5 M NaCl, 20 mM imidazole, pH 7.4), and then homogenized under high pressure using an ultra-high pressure homogenizer (Ningbo Xinzhi Biotechnology Co., Ltd., SCIENTZ-207A). The supernatant was collected by centrifugation at 8000 rpm and impurities were removed by filtration through a 0.22 μm filter membrane. (6) Purify the target protein using the AKTA Pure protein purifier. First, equilibrate the HisTrap HP protein purification column with buffer A, and load the supernatant at 3 mL / min. After loading, wash away unbound protein with buffer A until the A280 UV absorbance is close to 0 mAU. Perform linear elution with buffer B (20 mM PB, 0.5 M NaCl, 0.5 M imidazole, pH 7.4), and increase to 100% buffer B after 50 min. Collect the protein based on the UV value (VU280). (7) The collected samples were analyzed and identified using 4-20% protein pregels to determine the protein expression level.

[0061] The expression of 16 candidate antigen proteins is as follows: Figure 1 As shown.

[0062] Figure 1 The results showed that 16 candidate proteins were prepared and purified, and can be used for subsequent evaluation of immunization effects.

[0063] Example 2

[0064] Preliminary identification of effective antigen proteins

[0065] Mice (SPF-grade BALB / c mice) were immunized subcutaneously in the neck and back with the above 16 candidate antigen proteins. Each mouse received 20 μg of each protein mixed with 50 μg of aluminum hydroxide (Al(OH)3) and 10 μg of CpG2006 vaccine adjuvant. Ten mice were immunized with each protein three times, at days 0, 14, and 28. Fourteen days after the third immunization, mice were infected with Mycoplasma pneumoniae NCTC10119 (purchased from Beijing Zhongyuan Heju Biotechnology Co., Ltd., ATCC 15531) via lung delivery, with 1 × 10⁶ mice infected per mouse. 8In the CCU, mice were sacrificed 4 days after infection, and lung tissue was collected. PBS was added in equal weight proportions, and the tissue was ground and crushed. 10 mg of lung tissue was taken, and nucleic acid was extracted using the DNeasy blood & tissue kit (QIAGEN, 69504). The content of Mycoplasma pneumoniae was determined using digital PCR. The digital PCR detection reagent was the QIAcuity Probe PCR Kit (QIAGEN, 250102), and the digital PCR consumables were QIAcuity Nanoplate 26k 24-well (QIAGEN, 250001). The digital PCR primer and probe sequences were: upstream primer: 5'-GCAGTTGCTGGCGCTAAGTT-3' (SEQ ID NO.33), downstream primer: 5'-AGCGAGGTACGGTAGCGGTAT-3' (SEQ ID NO.34), and probe sequence: 5'-FAM-CTCGTTTTAGCGGGTACC-MGB-3' (SEQ ID NO.35). The digital PCR detection system consisted of: 10 μL of 4×Probe PCR Master Mix, 3.2 μL of upstream primer (10 μM), 3.2 μL of downstream primer (10 μM), 1.6 μL of probe (10 μM), 17 μL of nuclease-free water, and 5 μL of genomic template. The protective effect of the antigen was determined by its ability to reduce pathogen nucleic acid in lung tissue.

[0066] Due to the large number of proteins tested and the complexity of lung delivery infection procedures, the test was divided into four groups, each with an adjuvant control group (PBS + vaccine adjuvant). Based on bacterial count, three effective candidate protein antigens were identified: Ag3, Ag14, and Ag16. The results are as follows... Figure 2 As shown.

[0067] Example 3

[0068] Ag3 immune efficacy confirmed

[0069] First, the Ag3 candidate antigen protein and the positive control P1C protein were subjected to SDS-PAGE and molecular sieve analysis. The results are as follows: Figure 3 As shown, the results indicate that both the candidate protein and the positive control protein of this invention have clear primary target bands, and the SEC results show a single peak, indicating that the purified protein product is a monomer with homogeneous components. The P1C protein is the PIC disclosed in the invention entitled "A Recombinant Protein for Use as a Mycoplasma Pneumoniae Vaccine and Its Preparation Method and Application". 1376-1521 .

[0070] To further verify the immunoprotective effect of Ag3, the protein and the positive control P1C protein were simultaneously subjected to mouse immunoassay. The specific steps are as follows: (1) Purchase 30 SPF-grade BALB / c mice and randomly divide them into 3 groups; (2) Subcutaneous immunization was performed on the back of the neck. A PBS adjuvant control group, a P1C positive control group, and an Ag3 candidate antigen group were set up. Each mouse was immunized with 20 μg of each protein, mixed with 50 μg Al(OH3) and 10 μg CpG2006 adjuvant. Ten mice were immunized with each protein three times, on days 0, 14, and 28. Blood was collected from the tail tip on days 21 and 35 to determine the antibody titer of the protein after immunization. (3) Fourteen days after the third immunization, mice were infected with Mycoplasma pneumoniae NCTC10119 via lung delivery, with each mouse infected with 1×10⁻⁶ NCTC10119. 8 CCU; (4) Weigh the mice daily after infection. Sacrifice the mice 4 days after infection and take the lung tissue. Add PBS in equal proportions according to weight, grind and crush, take 10mg of lung tissue, extract nucleic acid using DNeasy blood & tissue kit (QIAGEN, 69504), and use digital PCR to determine the content of Mycoplasma pneumoniae. (5) After centrifuging the remaining tissue homogenate, the supernatant was collected and the contents of TNF-α and IL-1β in the homogenate were determined using an ELISA kit.

[0071] The results showed that both Ag3 and P1C protein positive controls could effectively stimulate the production of antigen-specific antibodies, and the antibody levels were comparable. Figure 4 Following viral infection, the weight loss in mice in the Ag3 and P1C protein-positive control group was less than that in the adjuvant control group. Figure 5 Meanwhile, both Ag3 and P1C protein positive controls significantly reduced the concentrations of TNF-α and IL-1β in the lungs after infection, indicating that they could alleviate the acute inflammatory response induced by infection. Compared with P1C, Ag3 showed a further decreasing trend in alleviating the acute inflammatory response in the lungs. Figure 6 Quantitative results of lung bacterial counts showed that the lung bacterial counts in mice in the Ag3 and P1C protein positive groups were significantly lower than those in the adjuvant control group. Figure 7 The test results further confirm the potential of the Ag3 antigen protein to be developed into a Mycoplasma pneumoniae vaccine.

[0072] As demonstrated by the above embodiments, the Ag3 antigen protein of the present invention can effectively stimulate the production of antigen-specific antibodies, showing a more significant reduction in pulmonary bacterial load, and can reduce the concentrations of TNF-α and IL-1β in the lungs. After challenge infection, the degree of weight loss is less than that in the adjuvant control group. This indicates that the Ag3 antigen protein has the potential to be developed into a Mycoplasma pneumoniae vaccine.

[0073] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. An antigen protein, characterized in that, The antigen protein has the amino acid sequence shown in SEQ ID NO.3, or an amino acid sequence that has at least 95% sequence identity with SEQ ID NO.

3.

2. A nucleic acid molecule, characterized in that, The nucleotide sequence comprising the antigen protein of claim 1, wherein the nucleotide encoding the amino acid sequence shown in SEQ ID NO. 3 is shown in SEQ ID NO.

19.

3. The use of the antigen protein of claim 1 or the nucleic acid molecule of claim 2 in the preparation of a vaccine for the prevention and / or treatment of Mycoplasma pneumoniae infection.

4. The use of the antigen protein of claim 1 or the nucleic acid molecule of claim 2 in the preparation of antibodies against Mycoplasma pneumoniae infection, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

5. A fusion protein, characterized in that, It includes the antigen protein as described in claim 1 and the intramolecular adjuvant.

6. The fusion protein according to claim 5, characterized in that, The intramolecular adjuvant includes a CTB carrier or an LTB carrier.

7. The use of the fusion protein according to claim 5 or 6 in the preparation of a vaccine for the prevention and / or treatment of Mycoplasma pneumoniae infection.

8. The use of the fusion protein of claim 5 or 6 in the preparation of an antibody against Mycoplasma pneumoniae infection, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

9. A vaccine, characterized in that, It includes the antigen protein as described in claim 1 or the fusion protein as described in any one of claims 5 to 6, as well as the vaccine adjuvant.

10. The vaccine according to claim 9, characterized in that, The vaccine adjuvant includes aluminum hydroxide and / or CpG2006.

11. A composition, characterized in that, This includes the antigen protein described in claim 1, the fusion protein described in any one of claims 5-6, or the vaccine described in claim 9.